Back to search results

Electronic Cigarette Temperature and Solvent Study

This study is looking at how different settings on electronic cigarettes (e-cigarettes) affect your body. Researchers want to understand if using e-cigarettes at a high temperature (275°C) versus a low temperature (200°C), or with different amounts of Propylene Glycol (90% versus 10%) in the liquid, changes certain markers in your body related to stress. They will measure a marker called 8-isoprostane in your breath. You might be able to join if you are 21 or older, currently use sub-ohm/mod or pod e-cigarette devices daily, and don't plan to quit nicotine during the study. The study aims to enroll 50 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific e-cigarettes and e-liquids to use. It plans to enroll 50 participants.
What's involved
You will be given a study e-cigarette and e-liquid to use. You will complete questionnaires and provide blood, breath, saliva, and cheek cell samples. Your e-cigarette use will be video recorded.
Compensation
Not stated in the trial record.
Follow-up
Your 8-isoprostane levels will be measured at the start, 5 minutes after using the study product, and again after two weeks of using the product at home.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07612696

Impact of Electronic Cigarette Temperature and Solvent on Biomarkers

Not Yet Recruiting
NAAges 21+InterventionalBasic science
Milton S. Hershey Medical Center
~50 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:High temperature wattage setting on electronic cigaretteLow temperature wattage setting on electronic cigaretteHigh concentration of Propylene GlycolLow concentration of Propylene Glycol

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
8-isoprostane in Exhaled Breath Condensate
Measured over Baseline prior to study product use in Phase 1
+11 more outcomes measured

Conditions

Oxidative Stress
Tobacco Use
Electronic Cigarettes

Explore related trials

Electronic CigarettesTobacco Use

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Zachary Bitzer, Ph.D. · PRINCIPAL_INVESTIGATOR · Penn State Hershey College of Medicine

Who to contact

Zachary Btizer, Ph. D.
[email protected]
717-531-4387
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

21 years of age or older
Normal pulmonary and cardiovascular function with no history of COPD or cardiovascular disease (excluding hypertension)
Current exclusive use of a sub-ohm/mod or pod EC devices (≥ 1mL e-liquid/per day, ≥6 mg/ml nicotine concentration, EC for ≥ 1 year)
No plan on quitting nicotine use over the course of the study
All other forms of nicotine must be used \<5 days out of the past 28 days.
Able to read and write in English
Have access to email and a smartphone/computer that has reliable internet connection

Exclusion

Women who are pregnant and/or nursing or trying to become pregnant
Unstable or significant medical condition in the past 3 months (e.g., recent heart attack or other serious heart condition, stroke, severe angina)
Respiratory diseases (e.g., exacerbations of asthma or COPD, require oxygen, require oral prednisone), kidney (e.g., dialysis) or liver disease (e.g., cirrhosis), severe immune system disorders (e.g., uncontrolled HIV/AIDS, multiple sclerosis symptoms) or any medical disorder/medication that may affect participant safety or biomarker data
Uncontrolled substance abuse or inpatient treatment for that condition in the past 6 months
Have immediate family or household members currently participating in this trial

What this trial measures

  • 8-isoprostane in Exhaled Breath CondensateBaseline prior to study product use in Phase 1

    8-isoprostane levels will be analyzed via LC-MS

  • 8-isoprostane in Exhaled Breath Condensate5 minutes after directed study product use in Phase 1

    8-isoprostane levels will be analyzed via LC-MS

  • 8-isoprostane in Exhaled Breath CondensateImmediately prior to study product use in Phase 2; visit occurs after 2 weeks of at home product use

    8-isoprostane levels will be analyzed via LC-MS

  • 8-isoprostane in Exhaled Breath Condensate5 minutes after directed study product use in Phase 2b; visit occurs after 2 weeks of at home product use

    8-isoprostane levels will be analyzed via LC-MS

  • 8-OHdG DNA Adducts in Buccal CellsBaseline prior to study product use in Phase 1

    8-OHdG-DNA adducts will be measured via LC-MS/MS

  • 8-OHdG DNA Adducts in Buccal Cells5 minutes after directed study product use in Phase 1

    8-OHdG-DNA adducts will be measured via LC-MS/MS

  • 8-OHdG DNA Adducts in Buccal CellsImmediately prior to study product use in Phase 2; visit occurs after 2 weeks of at home product use

    8-OHdG-DNA adducts will be measured via LC-MS/MS

  • 8-OHdG DNA Adducts in Buccal Cells5 minutes after directed study product use in Phase 2b; visit occurs after 2 weeks of at home product use

    8-OHdG-DNA adducts will be measured via LC-MS/MS

  • Total nicotine in Blood SamplesBaseline prior to study product use in Phase 1

    Nicotine levels will analyzed via LC-MS

  • Total nicotine in Blood Samples5 minute after directed study product use in Phase 1

    Nicotine level will be analyzed via LC-MS

  • Total nicotine in Blood SamplesImmediately prior to study product use in Phase 2; visit occurs after 2 weeks of at home product use

    Nicotine levels will be analyzed via LC-MS

  • Total nicotine in Blood Samples5 minutes after directed study product use in Phase 2b; visit occurs after 2 weeks of at home product use

    Nicotine levels will be analyzed via LC-MS